On August 5, 2026, the board of directors of Agenus Inc. increased its size from six to seven members and appointed Marco Tullio Marcucci as a Class II director effective immediately. Mr. Marcucci will serve until the 2029 annual meeting and joined the Corporate Governance and Nominating Committee. He receives an annual cash retainer of $75,000 plus a $7,500 committee retainer and was granted an option to purchase 7,500 shares vesting over three years. Agenus Inc. operates in the biotechnology industry, focusing on cancer immunotherapy.
